A Trial to Investigate the Efficacy and Safety of NW Low-Glu® in Patients With Type II Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

Also called NCT06140485

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
Natural Wellness Egypt (from the registry)
Registry
  • NCT NCT06140485
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06140485. Randomized; triple masking; primary purpose treatment. Start 2024-03 (anticipated); primary completion 2025-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trial to Investigate the Efficacy and Safety of NW Low-Glu® in Patients With Type II Diabetes Mellitus
Condition
Diabetes Mellitus, Type 2
Intervention (Dietary supplement)
NW Low-Glu®
Intervention (Drug)
Metformin
Lead sponsor
Natural Wellness Egypt (class: industry)

Record details

Record id
cardio:ct-nct06140485
Content hash
df3ff65354ca56314ec4358ec35910ad37b5ee397ecd858347cac516484f6e92